Aldosterone receptor antagonists for heart failure: Current status, future indications
Bertram Pitt, MD
University of Michigan School of Medicine, Ann Arbor, MI; investigator in the RALES, EPHESUS, and 4E trials
Sanjay Rajagopalan, MD
Mt. Sinai School of Medicine, New York, NY
Address: Sanjay Rajagopalan, MD, One Gustave Levy Place, Box 1030, New York, NY 10029; e-mail sanjay.Rajagopalan@mssm.edu
Dr. Pitt has indicated that he serves as a consultant for the Pfizer corporation.
ABSTRACTMany patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)—in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.